



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

Title: FUSED AZABICYCLIC
COMPOUNDS THAT INHIBIT
VANILLOID RECEPTOR SUBTYPE 1
(VR1) RECEPTOR

Case No.: 6888USP1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: February 23, 2004

Tanya Parent 2/23/04
Tanya Parent Date

TRANSMITTAL LETTER

Dear Sir:


Enclosed herewith for the patent application identified above entitled FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. References as cited on PTO 1449 (34 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
Lee, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623


Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lee, et al.

Serial No.: 10/634,678

Filed: August 5, 2003

Title: FUSED AZABICYCLIC
COMPOUNDS THAT INHIBIT
VANILLOID RECEPTOR SUBTYPE 1
(VR1) RECEPTOR

Case No.: 6888USP1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: February 23, 2004

Tanya Parent 2/23/04
Tanya Parent Date

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
Lee, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623

Johanna M. Corbin
Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants



DATE: February 23, 2004 Sheet 1_ of 2_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6888USP1

SERIAL NO.

10/634,678

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT(S)

Lee et al.

FILING DATE

August 5, 2003

GROUP

1614

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRAN- SLATION YES NO
	B1 03/014064	20.02.2003	WO			
	B2 02/08221	31.01.2002	WO			
	B3 00/50387	31.08.2000	WO			
	B4 1 344 579		FR			X

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Adams et al., "Dialkylaminoalkylquinolines," J. Chem. Soc. 3066-3071 (1957)
C2	Berge, et al. "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> 66:1 et seq. (1977)
C3	Cannon et al., "Synthesis of N-alkyl derivatives of 4-(2'-aminothyl)indole," J. Heterocyclic Chemistry 19:1195-1199 (1982)
C4	Caterina, et al., "Impaired Nociception and pain sensation in mice lacking the capsaicin receptor," <i>Science</i> 288:306-313 (2000)
C5	Caterina, et al., "The capsaicin receptor: a heat-activated ion channel in the pain pathway," <i>Nature</i> 389:816-824 (1997)
C6	Caterina, et al., "The Vanilloid Receptor: A Molecular gateway to the pain pathway," <i>Annual Review of Neuroscience</i> 24:487-517 (2001)
C7	Collier, et al., Br. J. Pharmacol. Chemother. 32:295-310 (1968)
C8	Craig et al., "Derivatives of aminoisoquinolines," J. Am. Chem. Soc. 64:783-784 (1942)
C9	Davies, "Indazole Derivatives: The synthesis of various amino- and hydroxy-indazoles and derived sulphonic acids," J. Chem. Soc. 2412-2423 (1955)
C10	Davis, et al., "Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia," <i>Nature</i> 405:183-187 (2000)
C11	Fieser et al., "A comparison of heterocyclic systems with benzene. VI. Quinines of the quinoline and isoquinoline series," J. Amer. Chem. Soc. 57:1840-1844 (1935)
C12	Forbes et al., "N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT _{1C} receptor antagonist," J. Med. Chem. 36:1104-1107 (1993)
C13	Fowler, "Intravesical treatment of overactive bladder," <i>Urology</i> 55(Supp 5A):60-64 (2000)

C14	Gall et al., "171. On a few derivatives of heterocyclic carbonic acids IV. Metal ions and biological action, 36 th report," <i>Helv. Chim. Acta</i> 38(171):1421-1423 (1955) with translation
C15	Giencke et al. "Desmethyl(trifluormethyl)actinomycine," <i>Liebigs Ann. Chem.</i> 6:569-579 (1990)
C16	Hayes, et al., "Cloning and functional expression of a human orthologue of rat vanilloid receptor-1," <i>Pain</i> 88:205-215 (2000)
C17	Honma et al., "Structure-based generation of a new class of potent Cdk4 inhibitors: New <i>de Novo</i> design strategy and library design," <i>J. Med. Chem.</i> 44:4615-4627 (2001)
C18	Kawasaki et al., "A new approach to 4-(2-aminoethyl)indoles via Claisen <i>ortho</i> -amide rearrangement of 3-hydroxy-2-methoxyindolines," <i>J. Chem. Soc. Chem. Commun.</i> 10:781-782 (1990)
C19	Kumar et al. "Antiparasitic agents: Part XV – synthesis of 2-substituted 1(3) <i>H</i> -imidazo[4,5- <i>f</i>]isoquinolines as anthelmintic agents," <i>Indian Journal of Chemistry</i> 31B:177-182 (1992)
C20	Lila et al., "Large scale preparation of protected 4-aminomethylbenzamidine. Application to the synthesis of the thrombin inhibitor, melagatran," <i>Synth. Comm.</i> 28:4419-4429 (1998)
C21	Mooney et al., "Potential antitumor agents, 10. Synthesis and biochemical properties of 5- <i>N</i> -alkylamino-, <i>N,N</i> -dialkylamino-, and <i>N</i> -alkylacetamido-1-formylisoquinoline thiosemicarbazones," <i>Journal of Medicinal Chemistry</i> 17(11):1145-1150 (1974)
C22	Mukkala et al., "124. New heteroromatic complexing agents and luminescence of their europium (III) and terbium(III) chelates," <i>Helvetica Chima Acta</i> 75:1621-1632 (1992)
C23	Naruto et al., "Photo-induced Friedel-Crafts reactions. IV> Indoleacetic acids," <i>Chemical and Pharmaceutical Bulletin, Tokyo, JP</i> 20(10):2163-2171 (1972)
C24	Nolano, et al., "Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation," <i>Pain</i> 81:135-145 (1999)
C25	Prescott, et al., <i>Methods in Cell Biology</i> , Academic Press, New York, N.Y. Vol. 14:33 et seq. (1976)
C26	Prijs et al. "9. On a few derivatives of heterocyclic carbonic acids I.. Metal ions and biological action, 16 th report," <i>Helv. Chim. Acta</i> 37:90-94 (1954) with translation
C27	Roe et al., "The preparation of heterocyclic fluorine compounds by the schiemann reaction. III. Some monofluoroisoquinolines," <i>J. Am. Chem. Soc.</i> , 73:687-689 (1951)
C28	Sato et al., "Construction of optically pure tryptophans from serine derived aziridine-2-carboxylates," <i>Tetrahedron Letters</i> 30(31):4073-4076 (1989)
C29	Taurins et al., "Thiazoloisoquinolines. IV. The synthesis and spectra of thiazolo[4,5- <i>h</i>]-and thiazolo[5,4- <i>f</i>]isoquinolines. The ultraviolet and proton magnetic resonance spectra of some substituted isoquinolines," <i>Canadian Journal of Chemistry</i> 49(24):4054-4061 (1971)
C30	Warpehoski et al., "Stereoelctronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065," <i>J. Med. Chem.</i> 31:590-603 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6888USP1	SERIAL NO. 10/634,678
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	APPLICANT(S) Lee et al.	
	FILING DATE August 5, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1	03/014064	20.02.2003	WO		
	B2	02/08221	31.01.2002	WO		
	B3	00/50387	31.08.2000	WO		
	B4	1 344 579	FR			X

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Adams et al., "Dialkylaminoalkylquinolines," J. Chem. Soc. 3066-3071 (1957)
C2	Berge, et al. "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> 66:1 et seq. (1977)
C3	Cannon et al., "Synthesis of N-alkyl derivatives of 4-(2'-aminothyl)indole," J. Heterocyclic Chemistry 19:1195-1199 (1982)
C4	Caterina, et al., "Impaired Nociception and pain sensation in mice lacking the capsaicin receptor," <i>Science</i> 288:306-313 (2000)
C5	Caterina, et al., "The capsaicin receptor: a heat-activated ion channel in the pain pathway," <i>Nature</i> 389:816-824 (1997)
C6	Caterina, et al., "The Vanilloid Receptor: A Molecular gateway to the pain pathway," <i>Annual Review of Neuroscience</i> 24:487-517 (2001)
C7	Collier, et al., Br. J. Pharmacol. Chemother. 32:295-310 (1968)
C8	Craig et al., "Derivatives of aminoisoquinolines," J. Am. Chem. Soc. 64:783-784 (1942)
C9	Davies, "Indazole Derivatives: The synthesis of various amino- and hydroxy-indazoles and derived sulphonic acids," J. Chem. Soc. 2412-2423 (1955)
C10	Davis, et al., "Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia," <i>Nature</i> 405:183-187 (2000)
C11	Fieser et al., "A comparison of heterocyclic systems with benzene. VI. Quinines of the quinoline and isoquinoline series," J. Amer. Chem. Soc. 57:1840-1844 (1935)
C12	Forbes et al., "N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT _{1C} receptor antagonist," J. Med. Chem. 36:1104-1107 (1993)
C13	Fowler, "Intravesical treatment of overactive bladder," <i>Urology</i> 55(Supp 5A):60-64 (2000)

C14	Gall et al., "171. On a few derivatives of heterocyclic carbonic acids IV. Metal ions and biological action, 36 th report," <i>Helv. Chim. Acta</i> 38(171):1421-1423 (1955) with translation
C15	Giencke et al. "Desmethyl(trifluormethyl)actinomycine," <i>Liebigs Ann. Chem.</i> 6:569-579 (1990)
C16	Hayes, et al., "Cloning and functional expression of a human orthologue of rat vanilloid receptor-1," <i>Pain</i> 88:205-215 (2000)
C17	Honma et al., "Structure-based generation of a new class of potent Cdk4 inhibitors: New <i>de Novo</i> design strategy and library design," <i>J. Med. Chem.</i> 44:4615-4627 (2001)
C18	Kawasaki et al., "A new approach to 4-(2-aminoethyl)indoles via Claisen <i>ortho</i> -amide rearrangement of 3-hydroxy-2-methoxyindolines," <i>J. Chem. Soc. Chem. Commun.</i> 10:781-782 (1990)
C19	Kumar et al. "Antiparasitic agents: Part XV – synthesis of 2-substituted 1(3) <i>H</i> -imidazo[4,5- <i>f</i>]isoquinolines as anthelmintic agents," <i>Indian Journal of Chemistry</i> 31B:177-182 (1992)
C20	Lila et al., "Large scale preparation of protected 4-aminomethylbenzamidine. Application to the synthesis of the thrombin inhibitor, melagatran," <i>Synth. Comm.</i> 28:4419-4429 (1998)
C21	Mooney et al., "Potential antitumor agents, 10. Synthesis and biochemical properties of 5- <i>N</i> -alkylamino-, <i>N,N</i> -dialkylamino-, and <i>N</i> -alkylacetamido-1-formylisoquinoline thiosemicarbazones," <i>Journal of Medicinal Chemistry</i> 17(11):1145-1150 (1974)
C22	Mukkala et al., "124. New heteroromatic complexing agents and luminescence of their europium (III) and terbium(III) chelates," <i>Helvetica Chimica Acta</i> 75:1621-1632 (1992)
C23	Naruto et al., "Photo-induced Friedel-Crafts reactions. IV> Indoleacetic acids," <i>Chemical and Pharmaceutical Bulletin, Tokyo, JP</i> 20(10):2163-2171 (1972)
C24	Nolano, et al., "Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation," <i>Pain</i> 81:135-145 (1999)
C25	Prescott, et al., <i>Methods in Cell Biology</i> , Academic Press, New York, N.Y. Vol. 14:33 et seq. (1976)
C26	Prijs et al. "9. On a few derivatives of heterocyclic carbonic acids I.. Metal ions and biological action, 16 th report," <i>Helv. Chim. Acta</i> 37:90-94 (1954) with translation
C27	Roe et al., "The preparation of heterocyclic fluorine compounds by the schiemann reaction. III. Some monofluoroisoquinolines," <i>J. Am. Chem. Soc.</i> , 73:687-689 (1951)
C28	Sato et al., "Construction of optically pure tryptophans from serine derived aziridine-2-carboxylates," <i>Tetrahedron Letters</i> 30(31):4073-4076 (1989)
C29	Taurins et al., "Thiazoloisoquinolines. IV. The synthesis and spectra of thiazolo[4,5- <i>h</i>]- and thiazolo[5,4- <i>f</i>]isoquinolines. The ultraviolet and proton magnetic resonance spectra of some substituted isoquinolines," <i>Canadian Journal of Chemistry</i> 49(24):4054-4061 (1971)
C30	Warpehoski et al., "Stereo-electronic factors influencing the biological activity and DNA interreaction of synthetic antitumor agents modeled on CC-1065," <i>J. Med. Chem.</i> 31:590-603 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)